Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18035005 | 0.81 | TUBB4A (0.43) | SLC6A2SLC6A4SLC6A3LMNAOPRM1 | |
| SCHEMBL16684889 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL5540524 | 0.77 | SRD5A1 (0.43) | SLC6A2SLC6A4SLC6A3HTR2CMAPT | |
| SCHEMBL13437405 | 0.75 | HTR2B (0.40) | HTR2CHTR2AHTR2BLMNAOPRM1 | |
| SCHEMBL5539441 | 0.75 | ESR1 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AOPRM1 | |
| SCHEMBL12363786 | 0.75 | POLB (0.41) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL6073564 | 0.74 | LMNA (0.55) | HTR2CHTR2AHTR2BLMNAOPRM1 | |
| SCHEMBL68109 | 0.74 | ACHE (0.51) | LMNABRD4NISCHACHE | |
| SCHEMBL13891861 | 0.74 | NISCH (0.39) | SLC6A2SLC6A4SLC6A3LMNAMAPT | |
| SCHEMBL16494499 | 0.73 | CACNA1G (0.52) | SLC6A2SLC6A4SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| EP-0438796-B1 | Process for the enantioselection synthesis of alkylated oxindoles used as intermediates in the preparation of physostigmine | HOECHST MARION ROUSSEL INC (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | SLC6A2 445/4885SLC6A4 282/4885SLC6A3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.